XML 48 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value - Additional Information (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Jul. 31, 2023
USD ($)
Installment
Apr. 07, 2022
Oct. 31, 2024
USD ($)
Jul. 31, 2024
USD ($)
Apr. 30, 2024
USD ($)
Installment
Apr. 30, 2022
USD ($)
Installment
Mar. 31, 2023
USD ($)
shares
Mar. 31, 2022
USD ($)
Jun. 30, 2021
USD ($)
Dec. 31, 2018
USD ($)
Installment
shares
Nov. 21, 2022
shares
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Interest expense due to passage of time and fixed payment schedule             $ 1,100        
Change in fair value of warrant liability             $ (61)        
2018 Notes | Series G Preferred Stock                      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Warrant issued to purchase shares | shares             613,333        
Contingent Consideration                      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Interest expense due to passage of time and fixed payment schedule               $ 900      
Warrant Liabilities                      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Warrant issued to purchase shares | shares                     5,000,000
Change in fair value of warrant liability             $ 100        
Integrated Diagnostics, Inc | Contingent Consideration                      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Business acquisition description             requires additional consideration to be paid by the Company to such shareholders upon attainment of a three-consecutive month        
Business acquisition contingent consideration gross margin target                 $ 2,000 $ 2,000  
Business acquisition contingent consideration gross margin target period                   7 years  
Integrated Diagnostics, Inc | Contingent Consideration | Third Amendment to APA Agreement                      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Contingent consideration number of installments | Installment           5          
Milestone payment           $ 2,000          
Percentage of interest on installment payments   10.00%                  
Integrated Diagnostics, Inc | Contingent Consideration | Scenario Forecast | Third Amendment to APA Agreement                      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Contingent consideration number of installments | Installment 3       1            
Milestone payment $ 3,000     $ 8,400 $ 5,000            
Exit fee payment     $ 6,100                
Integrated Diagnostics, Inc | Common Stock | Contingent Consideration                      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Business acquisition description             If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million.        
Contingent consideration shares | shares                   2,520,108  
Contingent consideration number of installments | Installment                   8  
Contingent consideration arrangements, common shares, redemption amount             $ 4,600     $ 37,000  
Repayments of debt             9,300        
Business combination contingent consideration final payment             $ 37,000        
Integrated Diagnostics, Inc | Common Stock | Contingent Consideration | Repurchase                      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Contingent consideration cash payment                   $ 37,000  
Minimum | Contingent Consideration                      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range             11.00%        
Maximum | Contingent Consideration                      
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                      
Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range             16.00%